Chemomab Therapeutics is a clinical-stage biotech firm that creates medicines for treating inflammation and fibrosis. They're known for CM-101, a humanized monoclonal antibody that treats primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc) by inhibiting the role of soluble chemokine CCL24. The business formerly operated under the name Anchiano Therapeutics and was established in 2011, with its headquarters based in Tel Aviv, Israel.